Skip to content

Study · Observational study · 2021

6 results

Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.

Zimner Rapuch S, Divino V, Norrbacka K, Boye K, Lebrec J, Rosilio M, DeKoven M, Guerci B

Diabetes therapy : research, treatment and education of diabetes and related disorders17 Apr 2021Cited by 6 (Europe PMC)

PMID33864629 (opens in a new tab)PMCIDPMC8099988 (opens in a new tab)DOI10.1007/s13300-021-01055-5 (opens in a new tab)PepBankPUB-33864629
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyOther

    In French patients with type II diabetes, dulaglutide was linked to longer median persistence than liraglutide.

    In plain wordsIn patients with diabetes, dulaglutide was linked to longer treatment persistence than liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseMedian persistence versus liraglutide
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Analysis
    Primary
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Median persistence
    373 days
    dulaglutide
    Median persistence
    205 days
    liraglutide

    Source sentences

    Summary
    Median persistence was longest for dulaglutide (373 days) versus liraglutide (205 days), exenatide QW (184 days) and exenatide BID (93 days).
    1 context sentence
    Summary · context
    This retrospective cohort analysis presents longitudinal data from approximately 7500 French retail pharmacies that filled GLP-1-RA prescriptions for GLP-1 RA-naïve patients with T2D ('index therapy': dulaglutide; once-weekly exenatide [exenatide QW]; twice-daily exenatide [exenatide BID]; liragluti…
  2. 02HumanObservational studyOther

    In French patients with type II diabetes, liraglutide was linked to shorter median persistence than dulaglutide.

    In plain wordsIn patients with diabetes, liraglutide was linked to shorter treatment persistence than dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseMedian persistence
    Study

    n: not reported in source

    Comparator
    Dulaglutide
    Analysis
    Primary
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Median persistence
    205 days
    liraglutide
    Median persistence
    373 days
    dulaglutide

    Source sentences

    Summary
    Median persistence was longest for dulaglutide (373 days) versus liraglutide (205 days), exenatide QW (184 days) and exenatide BID (93 days).
    1 context sentence
    Summary · context
    This retrospective cohort analysis presents longitudinal data from approximately 7500 French retail pharmacies that filled GLP-1-RA prescriptions for GLP-1 RA-naïve patients with T2D ('index therapy': dulaglutide; once-weekly exenatide [exenatide QW]; twice-daily exenatide [exenatide BID]; liragluti…
  3. 03HumanObservational studyOther

    In French patients with type II diabetes, dulaglutide was linked to longer median persistence than weekly exenatide.

    In plain wordsIn patients with diabetes, dulaglutide was linked to longer treatment persistence than weekly exenatide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseMedian persistence versus weekly exenatide
    Study

    n: not reported in source

    Comparator
    Exenatide once weekly
    Analysis
    Primary
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Median persistence
    373 days
    dulaglutide
    Median persistence
    184 days
    weekly exenatide

    Source sentences

    Summary
    Median persistence was longest for dulaglutide (373 days) versus liraglutide (205 days), exenatide QW (184 days) and exenatide BID (93 days).
    1 context sentence
    Summary · context
    This retrospective cohort analysis presents longitudinal data from approximately 7500 French retail pharmacies that filled GLP-1-RA prescriptions for GLP-1 RA-naïve patients with T2D ('index therapy': dulaglutide; once-weekly exenatide [exenatide QW]; twice-daily exenatide [exenatide BID]; liragluti…
  4. 04HumanObservational studyOther

    In French patients with type II diabetes, dulaglutide was linked to longer median persistence than twice-daily exenatide.

    In plain wordsIn patients with diabetes, dulaglutide was linked to longer treatment persistence than twice-daily exenatide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreaseMedian persistence versus twice-daily exenatide
    Study

    n: not reported in source

    Comparator
    Exenatide twice daily
    Analysis
    Primary
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Median persistence
    373 days
    dulaglutide
    Median persistence
    93 days
    twice-daily exenatide

    Source sentences

    Summary
    Median persistence was longest for dulaglutide (373 days) versus liraglutide (205 days), exenatide QW (184 days) and exenatide BID (93 days).
    1 context sentence
    Summary · context
    This retrospective cohort analysis presents longitudinal data from approximately 7500 French retail pharmacies that filled GLP-1-RA prescriptions for GLP-1 RA-naïve patients with T2D ('index therapy': dulaglutide; once-weekly exenatide [exenatide QW]; twice-daily exenatide [exenatide BID]; liragluti…
  5. 05HumanObservational studyOther

    In French patients with type II diabetes, persistence at 12 months was higher with dulaglutide than twice-daily exenatide.

    In plain wordsIn patients with diabetes, more patients continued dulaglutide than twice-daily exenatide at 12 months.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreasePersistence at 12 months
    Study

    n: not reported in source

    Comparator
    Exenatide twice daily
    Analysis
    Primary
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Persistence
    51%
    dulaglutide
    Persistence
    21%
    twice-daily exenatide

    Source sentences

    Summary
    Twelve months after treatment initiation, the percentage of persistent patients ranged from 51% (dulaglutide) to 21% (exenatide BID).
    1 context sentence
    Summary · context
    This retrospective cohort analysis presents longitudinal data from approximately 7500 French retail pharmacies that filled GLP-1-RA prescriptions for GLP-1 RA-naïve patients with T2D ('index therapy': dulaglutide; once-weekly exenatide [exenatide QW]; twice-daily exenatide [exenatide BID]; liragluti…
  6. 06HumanObservational studyOther

    In French patients with type 2 diabetes, treatment modification occurred less commonly with dulaglutide than with the other index GLP-1 RAs overall.

    In plain wordsIn patients with diabetes, dulaglutide was linked to fewer treatment changes than the other GLP-1 drugs studied, taken together.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseTreatment modification versus other index GLP-1 RAs
    Study

    n: not reported in source

    Comparator
    Other index GLP-1 RAs (liraglutide, exenatide QW, exenatide BID), pooled
    Outcome group
    Treatment adherence and retention · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Overall, treatment modification occurred less commonly for dulaglutide than for the other index GLP-1 RAs.
    1 context sentence
    Summary · context
    This retrospective cohort analysis presents longitudinal data from approximately 7500 French retail pharmacies that filled GLP-1-RA prescriptions for GLP-1 RA-naïve patients with T2D ('index therapy': dulaglutide; once-weekly exenatide [exenatide QW]; twice-daily exenatide [exenatide BID]; liragluti…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.